This case involves an appeal from Regeneron Pharmaceuticals, Inc.’s (Regeneron) efforts to prevent defendants from marketing biosimilar versions ...

An EMA committee has issued a positive opinion for a label extension that would allow six-month injection intervals for Eylea ...

all of which have potential biosimilars nearing the end of clinical development. The availability of Byooviz could also have an impact on Bayer and Regeneron's Eylea (aflibercept), which still has ...

Novartis' soon-to-be-divested Sandoz unit has positive clinical trial data in hand for a biosimilar of Amgen's blockbuster osteoporosis therapy Prolia (denosumab), clearing the way for regulatory ...